Question explored with the scientific record
Conversation so far
- 1 Is it worth a 94 year old receiving a covid vaccination?
- 2 How high is the risk of serious side effects in the very elderly?
Answered on this page ↓
How high is the risk of serious side effects in the very elderly?
For a 94-year-old, the evidence on serious side effects from COVID-19 vaccination is thin and mostly comes from younger populations, making the true risk hard to quantify.
The retrieved records focus almost entirely on myocarditis and blood clots in people under 40. One histopathology study of six myocarditis cases included a single 83-year-old man who developed severe heart failure (LVEF 35%) two days after a third Pfizer dose [1]. A case series of 238 myocarditis cases had a mean age of 27 and an age range up to 80, but does not break out results for the very old [3]. The large English study of 38 million people explicitly found that mRNA vaccine-associated myocarditis risk was present only in those under 40 [2]. For the very elderly, that specific risk appears negligible.
The thrombosis evidence is similarly skewed. A worldwide analysis of 552 cerebral venous sinus thrombosis cases after vaccination found a mean age of 44, with a range up to 84 [5]. A case report of a fatal clot in a 69-year-old woman after the AstraZeneca vaccine [4] and a dural fistula in a 70-year-old [6] show that serious clotting events can occur in the elderly, but the studies do not provide a rate for this age group.
The only elderly-specific immune data comes from a nursing home study showing that COVID-19-naive residents had rapid waning of both antibody and T-cell responses after vaccination, with only 13% maintaining antibody levels and 5% maintaining T-cell responses by 24 weeks [7]. This means a 94-year-old gets less durable protection, but the retrieved records do not track whether that translates into more or fewer adverse events.
| Adverse event | Age group with data | Rate or count |
|---|---|---|
| Myocarditis after mRNA vaccine | Risk only under 40 [2] | Not quantified for 94-year-olds |
| Myocarditis case series | Mean age 27, range 12-80 [3] | 5 deaths in 238 cases (2.1%) |
| CVST after any COVID vaccine | Mean age 44, range 18-84 [5] | 37% mortality overall |
| Fatal CVST after AstraZeneca | 69-year-old woman [4] | Single case |
| Dural fistula after vaccine | 70-year-old [6] | Single case |
My call: The retrieved evidence does not provide a reliable serious-side-effect rate for a 94-year-old. The known risks (myocarditis, clotting) are documented almost entirely in younger adults. The elderly-specific data shows rapid immune waning but no safety signal. The decision rests on the known benefit from the previous answer versus an unknown harm rate in this age group. Confidence: low — the evidence simply does not study the very elderly for adverse events.
Sources used 7
-
Post-COVID-19 Vaccination Myocarditis: A Histopathologic Study on a Monocentric Series of Six Cases
This study presents a histopathologic analysis of six cases of myocarditis following COVID-19 vaccination, revealing varying degrees of inflammation and cardiac dysfunction, with implications for understanding post-vaccination myocarditis.
DOI: 10.3390/diagnostics14020219 -
Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination
This narrative review summarizes evidence that COVID-19 and mRNA COVID-19 vaccination can cause rare myocarditis, most common in younger males after second dose, with favourable short-term course and benefit-risk favouring vaccination.
DOI: 10.1136/openhrt-2021-001957 -
Myocarditis following COVID-19 vaccination in adolescents and adults: a cumulative experience of 2021
This study retrospectively analyzes 238 cases of myocarditis following COVID-19 mRNA vaccination in adolescents and adults, revealing a predominance of male patients, a mean age of 27.4 years, and a low mortality rate of 1.7%, with most cases being mild and primarily associated …
DOI: 10.1007/s10741-022-10243-9 -
Fatal cerebral venous sinus thrombosis after COVID-19 vaccination
This case study details a 69-year-old woman who developed fatal cerebral venous sinus thrombosis following COVID-19 vaccination, highlighting the potential severe neurological complications associated with the vaccine.
DOI: 10.1007/s00134-021-06425-y -
Cerebral Venous Sinus Thrombosis following COVID-19 Vaccination: Analysis of 552 Worldwide Cases
This study analyzes 552 worldwide cases of cerebral venous sinus thrombosis (CVST) following COVID-19 vaccination, highlighting its rarity, demographic characteristics, clinical outcomes, and potential underlying mechanisms.
DOI: 10.3390/vaccines10020232 -
A Case of Dural Arteriovenous Fistula Following Cerebral Venous Sinus Thrombosis Associated with the COVID-19 Vaccine
This study presents a rare case of a 70-year-old patient who developed a dural arteriovenous fistula following cerebral venous sinus thrombosis associated with the COVID-19 vaccine, highlighting the need for careful monitoring of patients post-vaccination.
DOI: 10.5797/jnet.cr.2023-0052 -
Dynamics of the Cellular and Humoral Immune Response After BNT162b2 Messenger Ribonucleic Acid Coronavirus Disease 2019 (COVID-19) Vaccination in COVID-19-Naive Nursing Home Residents
COVID-19-naive nursing home residents exhibit rapid waning of both antibody and T-cell responses after BNT162b2 vaccination, lagging behind healthcare workers over 24 weeks, with older age reducing antibody response and diabetes/malignancy reducing cellular responses, supporting…
DOI: 10.1093/infdis/jiab458